Bioporto: Wrap up from yesterday's event
Today, we hosted an event with Bioporto, where the company’s SVP for Global Marketing & US Commercialization, Jennifer Zonderman, and CFO Niels Høj Nielsen participated. The focus of the event was on 'building the global commercial platform.'
SVP Jennifer Zonderman provided in-depth insights into the operational initiatives the company is undertaking to bring NGAL from research to clinical testing.
In addition to discussing the competitors Bioporto faces and the market structure, SVP Jennifer Zonderman explained why NGAL is unique in the context of AKI. For the first time, investors gained a deeper understanding of how the company is progressing not only in the crucial US market but also in the rest of the world (ROW).
Listen to the interview here: Interview with Bioporto
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:50 AM 23-10-2024.
Login required
This content is only available for logged in users
BioPorto
BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.
Read more on company page